Abstract
Background
The role of estrogen receptor (ER) status in the carcinogenesis of lung cancer and
its impact on prognosis remain unclear.
Materials and Methods
We previously reported a prospective, multicenter, molecular epidemiology study (Japan
Molecular Epidemiology for Lung Cancer Study [JME]). We examined the relationship
of ER status with reproductive and hormonal factors, mutational profile, and survival
using JME study data. Patients were enrolled between July 2012 and December 2013,
with follow-up until November, 2017.
Results
Among 441 ever- and 435 never-smokers, ER expression was observed in 46.4% and 53.5%,
respectively (P = .022). Hormone use and reproductive history of female patients were not associated
with ER status. Mutations in EGFR (P = .003), TP53 (P = .007), and CTNNB1 (P = .027) were significantly associated with ER expression. Multivariate analysis showed
that mutations in EGFR (P = .032) and CTNNB1 (P = .026) were significantly associated with ER expression, whereas TP53 mutations exhibited a trend toward significance (P = .059). Relapse-free survival (RFS) was longer in all the patients with ER-positive
tumors than those with ER-negative tumors (P = .021). RFS and overall survival were longer (P = .024, P = .011, respectively) in the stage I patients with ER-positive tumors than those
with ER-negative tumors.
Conclusion
ERβ expression is positively associated with EGFR mutations and negatively with TP53 and CTNNB1 mutations. ER-positive tumors can be associated with better prognosis of the patients,
suggesting that ER expression with coexisting EGFR mutations and wild-type TP53 contribute to the biology of non-small cell lung cancer.
Keywords
Abbreviations:
ER (estrogen receptor), NSCLC (non-small cell lung cancer), EGFR (epidermal growth factor receptor), TP53 (tumor protein p53), CTNNB1 (catenin beta 1), ALK (anaplastic lymphoma kinase), MET (mesenchymal-epithelial transition), PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), IHC (immunohistochemistry), SWOG (Southwest Oncology Group), RFS (relapse-free survival), OS (overall survival), P stage (pathological stage), NOS (not otherwise specified), BMI (body mass index), OR (odds ratio), CI (confidence interval), HR (hazard ratio)To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Lung CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The effect of advances in lung-cancer treatment on population mortality.N Engl J Med. 2020; 383: 640-649
- Molecular mechanisms of estrogen carcinogenesis.Annu Rev Pharmacol Toxicol. 1996; 36: 203-232
- Evaluating intrinsic and non-intrinsic cancer risk factors.Nat Commun. 2018; 9: 3490
- Japanese ethnicity compared with caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small cell lung cancer.J Thorac Oncol. 2010; 5: 1001-1010
- Biological action of catechol estrogens.J. Endocrinol. 1981; 85: 59-65
- Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor α and β and show biological responses to estrogen.Cancer Res. 2002; 62: 2141-2150
- Smoking, sex, and non-small cell lung cancer. steroid hormone receptors in tumor tissue (S0424).J Natl Cancer Inst. 2018; 110: 734-742
- Reproductive factors and lung cancer risk among never-smoking japanese women with 21 years of follow-up: a cohort study.Cancer Epidemiol Biomarkers Prev. 2021; 30: 1185-1192
- Expression of estrogen and progesterone receptors in non-small-cell lung cancer: immunohistochemical study.Anticancer Res. 1996; 16: 3803-3806
- Clinical implications of genomic discoveries in lung cancer.N Engl J Med. 2016; 374: 1864-1873
- Prospective analysis of oncogenic driver mutations and environmental factors: japan molecular epidemiology for lung cancer study.J Clin Oncol. 2016; 34: 2247-2257
Peter S Hammerman, D Neil Hayes, Matthew D Wilkerson, et al. Cancer genome atlas research network: comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012; 489:519–525.
- Somatic mutations affect key pathways in lung adenocarcinoma.Nature. 2008; 23: 1069-1075
- Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.Cell. 2012; 150: 1107-1120
- Genomic landscape of non-small cell lung cancer in smokers and never-smokers.Cell. 2012; 150: 1121-1134
- A rational diagnostic algorithm for the identification of ALK rearrangement in lung cancer: a comprehensive study of surgically treated Japanese patients.PLoS One. 2013; 8: e69794
- Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation.Clin Cancer Res. 2009; 15: 5359-5368
- Correlation between epidermal growth factor receptor mutations and nuclear expression of female hormone receptors in non-small cell lung cancer: a meta-analysis.J Thorac Dis. 2015; 7: 1588-1594
- The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers.J Thorac Cardiovasc Surg. 2005; 130: 979-986
- Differential role of estrogen receptor beta in early versus metastatic non-small cell lung cancer.Horm. Cancer. 2012; 3: 93-100
- Prognostic relevance of estrogen receptor alpha, beta and aromatase expression in non-small cell lung cancer.Steroids. 2016; 113: 5-13
AG Schwartz, AS Wenzlaff, GM Prysak, et al. Reproductive factors, hormone use, estrogen receptor expression and risk of non-small-cell lung cancer in women. J Clin Oncol 25:5785-92, 200723.
- Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites.Science. 1997; 277: 1508-1510
- Immunohistochemical expression of estrogen receptor in pulmonary adenocarcinoma.Appl Immunohistochem Mol Morphol. 2006; 14: 83-87
- Clinicopathological significance of oestrogen receptor expression in non-small cell lung cancer.J Int Med Res. 2017; 45: 51-58
- Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features.Nat Commun. 2021; 12: 2722
- Immune evasion before tumor invasion in early lung squamous carcinogenesis.Nature. 2019; 571: 570-575
- Influence of estrogen on the nsclc microenvironment: a comprehensive picture and clinical implications.Front Oncol. 2020; 10: 137
- Impact of tumor microenvironment on the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer.Cancer Sci. 2019; 110: 3244-3254
- p53 mutations in primary human lung tumors and their metastases.Mol Carcinog. 1994; 9: 105-109
- p53 mutations in human lung tumors.Cancer Res. 1992; 52: 1695-1698
- TP53 mutations in nonsmall cell lung cancer.J Biotechnol Biomed Sci. 2011; 9: 2011
- Genetic evidence for an independent origin of multiple preneoplastic and neoplastic lung lesions.Cancer Res. 1995; 55: 135-140
- p53 tumor suppressor gene: from the basic research laboratory to the clinic–an abridged historical perspective.Carcinogenesis. 1996; 17: 1187-1198
- Whole Genome Comparison of Allelic Imbalance between Noninvasive and Invasive Small-Sized Lung Adenocarcinomas.Cancer Res. 2009; 69: 1615-1623
- Apoptotic effects of over-expressed estrogen receptor-beta on LoVo colon cancer cell is mediated by p53 signalings in a ligand-dependent manner.Chin J Physiol. 2006; 49: 110-116
- Estrogen receptor prevents p53-dependent apoptosis in breast cancer.Proc Natl Acad Sci USA. 2012; 109: 18060-18065
- b-catenin contributes to lung tumor development induced by EGFR mutations.Cancer Res. 2014; 74: 5891-5902
- Inhibition of β-catenin enhances the anticancer effect of irreversible EGFR-TKI in EGFR-mutated non-small-cell lung cancer with a T790M mutation.J Thorac Oncol. 2015; 10: 93-101
- Molecular epidemiological study on passive smoking and estrogen receptor expression in never-smokers with non-small cell lung cancer.Osaka City Med J. 2016; 62: 77-84
Article info
Publication history
Published online: December 30, 2022
Accepted:
December 14,
2022
Received in revised form:
November 15,
2022
Received:
August 24,
2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
